6.75 USD
-0.29 (-4.12%)
7.07 USD
+0.32 (+4.74%)
We assign a fundamental rating of 3 out of 10 to ARDX. ARDX was compared to 525 industry peers in the Biotechnology industry. ARDX may be in some trouble as it scores bad on both profitability and health. ARDX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- In the past year ARDX has reported negative net income.
- In the past year ARDX has reported a negative cash flow from operations.
- In the past 5 years ARDX always reported negative net income.
- ARDX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ARDX's Return On Assets of -11.63% is amongst the best of the industry. ARDX outperforms 83.43% of its industry peers.
- Looking at the Return On Equity, with a value of -36.65%, ARDX is in the better half of the industry, outperforming 72.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.63% | ||
| ROE | -36.65% | ||
| ROIC | N/A |
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of ARDX (88.21%) is better than 90.48% of its industry peers.
- ARDX's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for ARDX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
2. Health
2.1 Basic Checks
- ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ARDX has been increased compared to 1 year ago.
- ARDX has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for ARDX is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.50, we must say that ARDX is in the distress zone and has some risk of bankruptcy.
- ARDX's Altman-Z score of 1.50 is fine compared to the rest of the industry. ARDX outperforms 65.33% of its industry peers.
- ARDX has a Debt/Equity ratio of 1.31. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of ARDX (1.31) is worse than 76.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.5 |
ROIC/WACCN/A
WACC8.93%
2.3 Liquidity
- ARDX has a Current Ratio of 4.41. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
- ARDX's Current ratio of 4.41 is in line compared to the rest of the industry. ARDX outperforms 51.05% of its industry peers.
- ARDX has a Quick Ratio of 4.11. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 4.11, ARDX perfoms like the industry average, outperforming 50.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 4.11 |
3. Growth
3.1 Past
- ARDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.09%, which is quite impressive.
- The Revenue has grown by 58.12% in the past year. This is a very strong growth!
- ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.15% yearly.
EPS 1Y (TTM)24.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)58.12%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%12.3%
3.2 Future
- The Earnings Per Share is expected to grow by 53.30% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 21.97% on average over the next years. This is a very strong growth
EPS Next Y-47.06%
EPS Next 2Y73.14%
EPS Next 3Y81.14%
EPS Next 5Y53.3%
Revenue Next Year22.08%
Revenue Next 2Y26.62%
Revenue Next 3Y28.25%
Revenue Next 5Y21.97%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ARDX. In the last year negative earnings were reported.
- A Price/Forward Earnings ratio of 41.51 indicates a quite expensive valuation of ARDX.
- Based on the Price/Forward Earnings ratio, ARDX is valued cheaper than 91.05% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of ARDX to the average of the S&P500 Index (24.29), we can say ARDX is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 41.51 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ARDX's earnings are expected to grow with 81.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.14%
EPS Next 3Y81.14%
5. Dividend
5.1 Amount
- No dividends for ARDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.75
-0.29 (-4.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-08 2026-01-08/amc
Earnings (Next)04-29 2026-04-29
Inst Owners67.27%
Inst Owner Change-0.5%
Ins Owners2.36%
Ins Owner Change-0.87%
Market Cap1.64B
Revenue(TTM)398.23M
Net Income(TTM)-56.55M
Analysts88.24
Price Target13.46 (99.41%)
Short Float %10.41%
Short Ratio6.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)70.63%
Min EPS beat(2)41.25%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)104.52%
Min EPS beat(4)-46.66%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)68.73%
EPS beat(12)9
Avg EPS beat(12)555.37%
EPS beat(16)12
Avg EPS beat(16)418.32%
Revenue beat(2)2
Avg Revenue beat(2)12.32%
Min Revenue beat(2)6.56%
Max Revenue beat(2)18.08%
Revenue beat(4)3
Avg Revenue beat(4)5.1%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)18.08%
Revenue beat(8)6
Avg Revenue beat(8)10.55%
Revenue beat(12)10
Avg Revenue beat(12)30.4%
Revenue beat(16)13
Avg Revenue beat(16)26.24%
PT rev (1m)13.79%
PT rev (3m)18.05%
EPS NQ rev (1m)-4.34%
EPS NQ rev (3m)174.02%
EPS NY rev (1m)0.42%
EPS NY rev (3m)28.45%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)5.92%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)4.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 41.51 | ||
| P/S | 4.12 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.63 | ||
| P/tB | 10.63 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.23
EYN/A
EPS(NY)0.16
Fwd EY2.41%
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS1.64
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.63% | ||
| ROE | -36.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.21% | ||
| FCFM | N/A |
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score5
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.31 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 64.96% | ||
| Cap/Sales | 0.43% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 4.11 | ||
| Altman-Z | 1.5 |
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)26.96%
Cap/Depr(5y)45.67%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-47.06%
EPS Next 2Y73.14%
EPS Next 3Y81.14%
EPS Next 5Y53.3%
Revenue 1Y (TTM)58.12%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%12.3%
Revenue Next Year22.08%
Revenue Next 2Y26.62%
Revenue Next 3Y28.25%
Revenue Next 5Y21.97%
EBIT growth 1Y41.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.98%
EBIT Next 3Y105.48%
EBIT Next 5Y73.54%
FCF growth 1Y18.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.19%
OCF growth 3YN/A
OCF growth 5YN/A
ARDELYX INC / ARDX FAQ
What is the ChartMill fundamental rating of ARDELYX INC (ARDX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ARDX.
Can you provide the valuation status for ARDELYX INC?
ChartMill assigns a valuation rating of 2 / 10 to ARDELYX INC (ARDX). This can be considered as Overvalued.
How profitable is ARDELYX INC (ARDX) stock?
ARDELYX INC (ARDX) has a profitability rating of 2 / 10.
Can you provide the financial health for ARDX stock?
The financial health rating of ARDELYX INC (ARDX) is 3 / 10.